Clofibride
Chemical compound
- C10AB10 (WHO)
- 3-(dimethylcarbamoyl)propyl 2-(4-chlorophenoxy)-2-methylpropanoate
- 26717-47-5
- 160134
- 140758
Y
- 0S9SLS3L93
- D07188 Y
- ChEMBL1697831
- DTXSID1022841
- Interactive image
- Clc1ccc(OC(C(=O)OCCCC(=O)N(C)C)(C)C)cc1
- InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3Y
- Key:CXQGFLBVUNUQIA-UHFFFAOYSA-NY
Clofibride is a fibrate. Clofibride is a derivative of clofibrate. In the body it is converted into 4-chlorophenoxyisobutyric acid (clofibric acid),[1] which is the true hypolipidemic agent.[2] So clofibride, just like clofibrate is a prodrug of clofibric acid.
References
- ^ "Clofibride".
- ^ Entry on Clofibrat. at: Römpp Online. Georg Thieme Verlag, retrieved 06. Mai 2020.
- v
- t
- e
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
